Reduced anxiety in the mice expressing mutant (N141I) presenilin 2

Journal of Neuroscience Research

Volumn 87, Issue 2, 2009, Pages 522-531

  Yuk, Dong Yeon ^a   Lee, Yong Kyung ^a   Nam, Sang Yoon ^a   Yun, Young Won ^a   Hwang, Dae Youn ^b   Choi, Dong Young ^c   Oh, Ki Wan ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Pusan National University   (South Korea)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

aminobutyric acid receptor; Alzheimer's disease; Anxiety; C Fos; Presenilin 2

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; MUTANT PROTEIN; PRESENILIN 2; PROTEIN C FOS;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DATA ANALYSIS; GENE MUTATION; HIPPOCAMPUS; LOCOMOTION; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; BRAIN; GENETICS; HYPERKINESIA; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; ANXIETY; BLOTTING, WESTERN; BRAIN; HYPERKINESIS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MUTATION; PRESENILIN-2; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, GABA-A;

EID: 62849112172     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21861     Document Type: Article

References (57)

1. Alves da Costa C, Paitel E, Mattson MP, Amson R, Telerman A, Ancolio K, Checler F, Mattson MP. 2002. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc Natl Acad Sci U S A 19:4043-4048.
2. Araki W, Yuasa K, Takeda S, Takeda K, Shirotani K, Takahashi K, Tabira T. 2001. Pro-apoptotic effect of presenilin 2 (PS2) overexpression is associated with down-regulation of Bcl-2 in cultured neurons. Neurochemistry 79:1161-1168.
3. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM. 2001. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891:42-53.
4. Beck CH, Fibiger HC. 1995. Conditioned fear-induced changes in behavior and in the expression of the immediate early gen c-fos: with and without diazepam pretreatment. J Neurosci 15:709-720.
5. A receptors rendered diazepaminsensitive by point-mutation α-subunit. FEBS Lett 431:400-404.
6. Bilkei-Gorzó A, Otto M, Zimmer A. 2008. Environmental modulation of anxiety-related neuronal activity and behaviors. Behav Brain Res 186: 289-292.
7. Borchelt DR, Ratovitski T, Van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. 1997. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939-945.
8. Buxbaum JD, Choi EK, Luo Y, Lilliehook C, Crowley AC, Merriam DE, Wasco W. 1998. Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat Med 4:1177-1181.
9. Chung JA, Cummings JL. 2000. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease. Neurol Clin 18:829-846.
10. Crane W, French KR, Buller KM. 2005. Patterns of neuronal activation in the rat brain and spinal cord in response to increasing durations of restraint stress. Stress 8:199-211.
11. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van Der Putten H. 2003. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 17:2409-2417.
12. Cullinan WE, Herman JP, Battaglia DF, Akil H, Watson SJ. 1995. Pattern and time course of immediate early gene expression in rat brain following acute stress. Neuroscience 64:477-505.
13. Culmsee C, Landshamer S. 2006. Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr Alzheimer Res 3:269-283.
14. A modulators. CNS Spectr 10:21-27.
15. Dayas CV, Buller KM, Crane JW, Xu Y, Day TA. 2001. Stressor categorization: acute physical and psychological stressors elicit distinctive recruitment patterns in the amygdala and in medullary noradrenergic cell groups. Eur J Neurosci 14:1143-1152.
16. Engin E, Treit D. 2007. The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol 18:365-374.
17. Figueiredo HF, Bruestle A, Bodie B, Dolgas CM, Herman JP. 2003. The medial prefrontal cortex differentially regulates stress-induced c- fos expression in the forebrain depending on type of stressor Eur J Neurosci 18:2357-2364.
18. Franklin KBJ, Paxinos G. 1997. The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
19. Garakani A, Mathew SJ, Charney DS. 2006. Neurobiology of anxiety disorders and implications for treatment. Mount Sinai J Med 73:941-949.
20. He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, Zhang Y, Xu H, Tempier A, Li X, Li XM. 2007. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging [E-pub ahead of print].
21. Holmes A, Parmigiani S, Ferrari PF, Palanza P, Rodgers RJ. 2000. Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Physiol Behav 71:509-516.
22. Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS, Kim YK. 2002. Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J 16:805-813.
23. Janicki S, Monteiro MJ. 1997. Increased apoptosis arising from increased expression of the Alzheimer's disease-associated presenilin-2 mutation (N141I). J Cell Biol 139:485-495.
24. Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW. 2005. Lifelong immunisation with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 130:667-684.
25. Kash SF, Tecott LH, Hodge C, Baekkeskov S. 1999. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A 96:1698-1703.
26. Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C. 2002. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation, Brain Res 956:36-44.
27. Lalonde R, Lewis TL, Strazielle C, Kim H, Fukuchi K. 2003. Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. Brain Res 977:38-45.
28. Lambert JC, Amouyel P. 2007. Genetic heterogeneity of Alzheimer's disease: complexity and advances. Psychoneuroendocrinology 32(Suppl 1):S62-S70.
29. Lee KW, Lee SH, Kim H, Song JS, Yang SD, Paik SG, Han PL. 2004. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J Neurosci Res 76:572-580.
30. Lee SM, Lee JW, Song YS, Hwang DY, Kim YK, Nam SY, Kim DJ, Yun YW, Yoon DY, Hong JT. 2005. Ryanodine receptor-mediated interference of neuronal cell differentiation by presenilin 2 mutation. J Neurosci Res 82:542-550.
31. Lee SY, Hwang DY, Kim YK, Lee JW, Shin IC, Oh KW, Lee MK, Lim JS, Yoon DY, Hwang SJ, Hong JT. 2006. PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J 20:151-153.
32. Linden AM, Greene SJ, Bergeron M, Schoepp DD. 2004. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29:502-513.
33. McQuade JM, Tamashiro KL, Wood GE, Herman JP, McEwen BS, Sakai RR, Zhang J, Xu M. 2006. Deficient hippocampal c-fos expression results in reduced anxiety and altered response to chronic stress in female mice. Neurosci Lett 403:125-130.
34. Molinuevo JL, Pintor L, Peri JM, Lleó A, Oliva R, Marcos T, Blesa R. 2005. Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias. Am J Alzheimers Dis Other Demen 20: 233-238.
35. B receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29:1050-1062.
36. Morris R. 1984. Developments of water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
37. Ognibene E, Middei S, Daniele S, Adriani W, Ghirardi O, Caprioli A. 2005. Aspects of spatial memory and behavioural disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav Brain Res 156:225-232.
38. Papadopoulos T, Korte M, Eulenburg V, Kubota H, Retiounskaia M, Harvey RJ, Harvey K, O'Sullivan GA, Laube B, Hülsmann S, Geiger JR, Betz H. 2007. Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice. EMBO J 26:3888-3899.
39. Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. 2006. Genetics, transcriptomics, and proteomics of Alzheimer's disease. J Clin Psychiatry 67:652-670.
40. Pellow S, File SE. 1986. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test foe anxiety in the rat. Pharmacol Biochem Behav 24:525-526.
41. Pugh PL, Ahmed SF, Smith MI, Upton N, Hunter AJ. 2004. A behavioural characterisation of the FVB/N mouse strain. Behav Brain Res 155:283-289.
42. Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D. 2007. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 178:18-28.
43. Quirk G, Armony JL, LeDoux JE. 1997. Fear conditioning enhances different temporal components of tone-evoked spike trains in auditory cortex and lateral amygdala. Neuron 19:613-624.
44. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. 2007. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 6:54-65.
45. Ritchie K, Lovestone S. 2002. The dementias. Lancet 360:1759-1766.
46. Sasaki K, Fan LW, Tien LT, Ma T, Loh HH, Ho IK. 2002. The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. Brain Res 57:689-694.
47. Seo JJ, Lee SH, Lee YS, Kwon BM, Ma Y, Hwang BY, Hong JT, Oh KW. 2007. Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog Neuropsychopharmacol Biol Psychiatry 31:1363-1369.
48. Shah AA, Treit D. 2003. Excitotoxic lesions of the medial prefrontal cortex attenuate fear responses in the elevated-plus maze, social interaction and shock probe burying tests. Brain Res 969:183-194.
49. Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Marksteiner J, Ransmayr G, Schmidt H, Stögmann E, Friedrich J, Wehringer C. 2008. Sex differences in Alzheimer's disease. Neuropsychiatry 22:1-15.
50. Singewald N, Salchner P, Sharp T. 2003. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53:275-283.
51. Touma C, Ambrée O, Görtz N, Keyvani K, Lewejohann L, Palme R, Paulus W, Schwarze-Eicker K, Sachser N. 2004. Age- and sex-dependent development of adrenocortical hyperactivity in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 25:893-904.
52. Võikar V, Kõks S, Vasar E, Rauvala H. 2001. Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav 72:271-281.
53. Whiting PJ. 2006. GABA-A receptors: a viable target for novel anxiolytics? Curr Opin Pharmacol 6:24-29.
54. Windle RJ, Kershaw YM, Shanks N, Wood SA, Lightman SL, Ingram CD. 2004. Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J Neurosci 24:2974-2982.
55. Wislowska-Stanek A, Zienowicz M, Lehner M, Taracha E, Bidziński A, Maciejak P, Skórzewska A, Szyndler J, Paẑnik A. 2005. Buspirone attenuates conditioned fear-induced c-Fos expression in the rat hippocampus. Neurosci Lett 389:115-120.
56. Zaman SH, Parent A, Laskey A, Lee MK, Borchelt DR, Sisodia SS, Malinow R. 2000. Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol Dis 7:54-63.
57. Zhang J, Zhang D, McQuade JS, Behbehani M, Tsien JZ, Xu M. 2002. c- fos Regulates neuronal excitability and survival. Nat Genet 30:416-420.